Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report
- PMID: 9249780
- DOI: 10.1093/ndt/12.7.1425
Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report
Abstract
Background: The incidence of recurrence of haemolytic-uraemic syndrome (HUS) in renal allografts appears to vary by centre, with the highest rates reported from the University of Minnesota. It is possible that the high rate of HUS recurrence at this institution reflects a transplant population skewed towards patients with a form of HUS that is more likely to recur in the allograft.
Methods: This study examined whether the initial episode of HUS in the native kidneys was preceded by a diarrhoeal prodrome ('classical HUS') or not ('atypical HUS'), and evaluated transplant outcomes in 24 patients who received 36 transplants at the University of Minnesota between 31 May 1972 and 31 December 1994.
Results: Eighteen of the 24 patients had atypical HUS, three had classical HUS, and in three patients the presence or absence of a diarrhoeal prodrome could not be determined. Recurrent HUS, defined as microangiopathic haemolytic anaemia, thrombocytopenia, renal insufficiency, and allograft biopsy findings compatible with HUS, occurred 16 times in 14 grafts in 11 patients. Nine of these patients had atypical HUS, one had classical HUS, and in one the nature of the prodrome could not be determined. Eleven of the 14 initial recurrences took place within 2 months of transplant. Recurrence was not more frequent in patients who received cyclosporin or antilymphocyte preparations. Actuarial analysis using matched controls showed poorer graft survival in patients with a primary diagnosis of HUS (P = 0.007), due to the high frequency of graft loss in HUS patients with recurrence.
Conclusion: Based upon these data and a review of the literature, it can be concluded that the risk of recurrence of HUS in the allograft is confined almost entirely to patients with atypical forms of HUS.
Similar articles
-
Renal transplantation in patients with classical haemolytic-uraemic syndrome.Pediatr Nephrol. 1991 Sep;5(5):607-11. doi: 10.1007/BF00856651. Pediatr Nephrol. 1991. PMID: 1911148
-
Post-transplantation outcome of patients with hemolytic-uremic syndrome: update.Pediatr Nephrol. 1991 Jan;5(1):162-7. doi: 10.1007/BF00852876. Pediatr Nephrol. 1991. PMID: 2025529
-
Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population.Nephrol Dial Transplant. 2013 Apr;28(4):1031-8. doi: 10.1093/ndt/gfs549. Epub 2013 Jan 8. Nephrol Dial Transplant. 2013. PMID: 23300261
-
Thrombotic microangiopathy in renal transplantation.Ann Transplant. 2002;7(1):28-33. Ann Transplant. 2002. PMID: 12221901 Review.
-
Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Nephrology (Carlton). 2016. PMID: 26988663 Review.
Cited by
-
Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate.Pediatr Nephrol. 2007 Jun;22(6):874-80. doi: 10.1007/s00467-007-0438-x. Epub 2007 Feb 13. Pediatr Nephrol. 2007. PMID: 17295030
-
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Pediatr Nephrol. 2019. PMID: 30402748 Free PMC article. Review.
-
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Clin Exp Immunol. 2008 Feb;151(2):199-209. doi: 10.1111/j.1365-2249.2007.03558.x. Epub 2007 Dec 7. Clin Exp Immunol. 2008. PMID: 18070148 Free PMC article. Review.
-
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.Clin J Am Soc Nephrol. 2009 Jan;4(1):201-6. doi: 10.2215/CJN.02170508. Epub 2008 Nov 12. Clin J Am Soc Nephrol. 2009. PMID: 19005013 Free PMC article.
-
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.Blood. 2006 Aug 15;108(4):1267-79. doi: 10.1182/blood-2005-10-007252. Epub 2006 Apr 18. Blood. 2006. PMID: 16621965 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical